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Abstract
The aim of this study was to investigate the relationship between antimicrobial use and the
occurrence of antimicrobial resistance in the digestive and respiratory tract in three different
production systems of food producing animals. A longitudinal study was set up in 25 Belgian
bovine herds (10 dairy, 10 beef, and 5 veal herds) for a 2 year monitoring of antimicrobial
susceptibilities in E. coli and Pasteurellaceae retrieved from the rectum and the nasal cavity,
respectively. During the first year of observation, the antimicrobial use was prospectively
recorded on 15 of these farms (5 of each production type) and transformed into the treat-
ment incidences according to the (animal) defined daily dose (TIADD) and (actually) used
daily dose (TIUDD). Antimicrobial resistance rates of 4,174 E. coli (all herds) and 474 Pas-
teurellaceae (beef and veal herds only) isolates for 12 antimicrobial agents demonstrated
large differences between intensively reared veal calves (abundant and inconstant) and
more extensively reared dairy and beef cattle (sparse and relatively stable). Using linear
mixed effect models, a strong relation was found between antimicrobial treatment inci-
dences and resistance profiles of 1,639 E. coli strains (p<0.0001) and 309 Pasteurellaceae
(p0.012). These results indicate that a high antimicrobial selection pressure, here found to
be represented by low dosages of oral prophylactic and therapeutic group medication, con-
verts not only the commensal microbiota from the digestive tract but also the opportunistic
pathogenic bacteria in the respiratory tract into reservoirs of multi-resistance.
Introduction
Associations between antimicrobial use and the prevalence of resistance in commensal faecal
E. coli of cattle have been documented [1–3] but that detailed records on the antimicrobial regi-
mens (e.g. dose) are limited. Such detailed records retrieved from swine production have
allowed to show that many applied antimicrobial regimens deviate from leaflet instructions
[4], which on their turn influence the occurrence of antimicrobial resistance in faecal Entero-
bacteriaceae [5]. No such information is currently available with regard to bovine livestock.
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Large variations in antimicrobial resistance profiles of Pasteurellaceae between different
bovine herds complicate empirical antimicrobial therapy of bovine respiratory disease [6,7].
Inclusion of these opportunistic pathogenic bacteria in studies exploring relationships with
antimicrobial use might aid to explain different stakeholders of the clinical relevance of antimi-
crobial resistance.
The purpose of the present multi-centre study was to find associations between antimicro-
bial consumption data and the occurrence of antimicrobial resistance profiles in the bovine
digestive (E. coli) and upper respiratory tract (Pasteurellaceae). The unit of measurements
applied are derived from the Defined Daily Dose (DDD) methodology, which is recommended
by the WHO to ensure comparison of selection pressure over time exerted between different
niches [4].
Materials and Methods
Selection of the herds
An intensive monitoring programme on antimicrobial drug use was set up in 25 cattle herds in
Belgium (Flanders) from April 2002 until January 2005. The participating herds were selected
from the Belgian identification and registration system for livestock (SANITEL) and from the
clients of the ambulatory clinic of the Faculty of Veterinary Medicine (Ghent University), and
consisted of 10 dairy herds with a minimum of 40 lactating cows (Holstein Friesian), 10 beef
herds (Belgian White Blue) with at least 30 newborn calves a year, and 5 veal calf farms. A key
inclusion criterion was the willingness of the farmer to cooperate at the initiation of the survey.
Breeds were Holstein Friesian and Belgian Blue in the dairy and the beef herds, respectively,
except for two dairy herds where approx. 15% of the animals were Belgian Blue or mixed
breeds. In most of the veal herds, several age groups (organised in pens) of predominantly male
Holstein Friesian calves were present of which only one group was monitored. The size of the
monitored groups varied between 144 and 594 animals. A further inclusion criterion consisted
in the absence of other livestock animal species (e.g. swine, poultry) bred by the selected farms,
so that interference of resistance selection due to antibiotic use for these animals was excluded.
Herds taking part in the study were quality label certified.
Study design
During the two year longitudinal survey, the 10 beef herds (B1-B10) were visited 4 times (every
six months; time points I, II, III, IV) while the 10 dairy herds (D1-D10) were visited 6 times
(every three months; time points I, II, III, IV, V, VI). The five veal herds (V1-V5) were moni-
tored twice during one production cycle of approximately six months, at approximately 4 (T1)
and 24 weeks (T2) after arrival at the farm (deviation in days ± 5). An overview of the study
design with respect to sampling, number of animals, and their distribution over the different
herd types is given in Table 1. Rectal samples consisted of taking approximately 5 g fresh faeces
in a sterile recipient, while nasopharyngeal samples were obtained by means of cotton swabs
(Venturi Transsystem1, Copan). All samples were stored at 5 +/- 3°C and bacteriological
investigations were set up within 24 hours after arrival in the laboratory.
During the first year of monitoring in the 5 dairy and 5 beef herds, and during the full pro-
duction cycle of the 5 veal calf herds, farmers were asked to continuously keep detailed antimi-
crobial consumption records, which consisted of the date of treatment, identification of the
treated animal (ear tag), indication of treatment, body weight of the treated animal (weighed,
estimated or determined by means of breed specific growth tables, product name, dose, admin-
istration route, and duration. The collected data were validated by checking treatment records
supplied by the respective herd veterinarians. In case more than 10% deviations were noticed
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during this comparative control procedure, antimicrobial consumption records were consid-
ered insufficient en not retained for further analysis.
Processing of antimicrobial consumption records
Antimicrobial consumption records were converted into treatment incidences per farm (and
per sample moment on the veal calves) based on the (animal) Defined Daily Dose (ADD) and
used daily dose (UDD) by means of the formulae presented in Fig 1 [8]. ADD was defined as
the average maintenance dose per day per kg animal of a drug for its main indication (equals
animal defined daily dose or ADD [9]. DDD values were estimated based on the dosage recom-
mendations of the Belgian compendia for veterinary drugs and are included in Tables 2–4. The
data on drug use presented in this study were classified according to the ATCvet classification
system [10]. The DDD were expressed per kg animal, except for the intramammary and intra-
uterine formulations. For these preparations, the unit dose (UD) was used [11], where one UD
equals the number of applications to be administered per 24 hours per quarter (expressed in
mg) in the case of mastitis treatment, 4 applicators (expressed in mg) in the case of dry cow
therapy, and the recommended 24 hour dose in the case of intra-uterine treatments. For other
long-acting preparations, the recommended dosage was transferred into a 24 hours dose. The
range of recommended doses was limited, except for ampicillin, amoxicillin, trimethoprim-sul-
phonamide combinations, and tetracycline for intra-uterine use (Tables 2–4). In contrast to
the ADD which is based on the leaflet of a certain product for its main indication (national reg-
istration), the UDD reflects the actually administered dose per day per kg of animal based on
the (individual) animal records.
For the dairy and the beef herds, the population at risk was defined as all cattle present in
the herd during the observation period due to the (globally) constant animal population
Table 1. Overview of the study design with respect to sampling scheme to monitor antimicrobial resistance in target bacteria.
Herd type N herds N sample periods (intensity) N Animals Target bacteria (ecosystem)
Dairy herds 10 6 (every 3 months) 50%a E. coli (digestive tract)
Beef herds 10 4 (every 6 months) 50%a E. coli (digestive tract)
P. multocida/M. haemolytica (respiratory tract)
Veal calves 5 2 (start and end of production cycle) 20% E. coli (digestive tract)
P. multocida/M. haemolytica (respiratory tract)
a On each sample occasion 50% of animals within following age categories were sampled: 0–0.5; 0.5–1; 1–2, >2 years. E: Escherichia; P: Pasteurella; M:
Mannheimia
doi:10.1371/journal.pone.0146488.t001
Fig 1. Formulae for the calculation of the treatment incidence (TI) based on the animal defined daily
dose (ADD; TIADD) and used daily dose (UDD; TIUDD).
doi:10.1371/journal.pone.0146488.g001
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throughout the study period in these herds. In the veal herds, only the number of animals in
the monitored age group was considered as being at risk. The number of animals present in the
herds was available from the Belgian identification and registration system (SANITEL) at the
beginning and at the end of the observation period. For the dairy and beef herds, the observa-
tion period was the first year of monitoring. To calculate the kg of animals at risk in the dairy
and the beef herds, the animals were divided in 4 age categories (<6 months, 6–12 months,
13–24 months and>24 months) and the average number of animals in each age category was
multiplied by the average weight of an animal of that specific age category. To determine the kg
Table 2. Treatment incidences (min-max) based on the animal unit dose (UD; TIUD) and prescribed daily dose (UDD; TIUDD) of the topical antimicro-
bial drugs in the different herd types.
Active substance ATCveta Indication UD (mg) Dairy herds Beef herds
Intramammary drugs TIUD TIUDD TIUD TIUDD
Procaine penicillin+ neomycin QJ51RC Md 500 0.07 0.03 - -
(0.00–0.43) (0.00–0.22)
Cloxacillin QJ51CF M 100 0.23 0.06 - -
(0.00–1.14) (0.00–0.31)
Cloxacillin QJ51CF De 2200 0.55 0.55 - -
(0.00–1.11) (0.00–1.11)
Nafcillin+benzylpenicillin+DHSb NAc M 100 0.59 0.45 0.06 0.06g
(0.00–1.42) (0.00–1.21) (0.00–0.49) (0.00–0.49)
Nafcillin+benzylpenicillin+DHS NA D 400 0.24 0.24 - -
(0.00–1.22) (0.00–1.22)
Cefquinome QJ51DA M 150 0.43 0.60 - -
(0.00–1.02) (0.00–0.97)
Cefalexin QJ51DA M 400 0.35 0.39 - -
(0.00–2.05) (0.00–2.31)
Lincomycin+neomycin QJ51RF M 660 0.17 0.29 0.03 0.03g
(0.00–0.43) (0.00–0.71) (0.00–0.30) (0.00–0.30)
Pirlimycin QJ51FF M 50 0.21 0.10 - -
(0.00–1.03) (0.00–0.51)
Total 2.83 2.71 0.09 0.09
(1.81–3.70) (0.94–3.83) (0.00–0.79) (0.00–0.79)
Intra-uterine drugs
Cefapirin QG01DA Vf 500 0.17 0.16 <0.01 <0.01
(0.00–0.78) (0.00–0.77) (0.0–0.02) (0.0–0.02)
Chlortetracycline hydrochloride QG01AA V 1500 0.25 0.16 0.78 1.07
(0.00–0.52) (0.00–0.34) (0.36–1.08) (0.39–1.62)
Total 0.42 0.32 0.78 1.07
(0.00–1.27) (0.00–1.11) (0.38–1.08) (0.39–1.62)
Grand total topical use 3.25 3.03 0.87 1.16
aAnatomical Therapeutic Chemical classiﬁcation system for Veterinary medicinal products
bdihydrostreptomycin
cnot available
dM: mastitis
eD: dry cow therapy
fV: variable (prophylactic and/or therapeutic)
g TIUD values were used to calculate the total TIUDD
doi:10.1371/journal.pone.0146488.t002
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Table 3. Average treatment incidences (min-max) based on animal defined daily dose (ADD; TIADD) and used dose (UDD; TIPDD) of the parenteral
antimicrobial drugs in the three different herd types.
Active substance ATCveta ADD Dairy herds Beef herds Veal herds
(mg/kg) TIADD TIUDD TIADD TIUDD TIADD TIUDD
Penethamaat hydroiodide QJ01CE 12.5 0.04 0.03 - - - -
(0.00–0.23) (0.00–0.18)
Procaine benzylpenicillin QJ01CE 12 0.58 0.15 2.12 0.87 - -
(0.00–1.63) (0.00–0.27) (0.00–4.39) (0.00–1.70)
Procaine benzathine benzylpenicillin LAb QJ01CE 3 0.32 0.17 0.54 0.29 - -
(0.00–0.72) (0.00–0.38) (0.00–1.35) (0.00–0.79)
Procaine benzylpenicillin+DHSc QJ01RC 8 0.52 0.25 0.04 0.02 0.04 0.01
(0.00–3.24) (0.00–1.58) (0.00–0.42) (0.00–0.12) (0.00–0.30) (0.00–0.10)
Procaine benzylpenicillin+neomycin QJ01RC 10 0.25 0.21 0.84 0.74 0.05 0.03
(0.00–0.99) (0.00–0.96) (0.03–1.94) (0.03–1.82) (0.00–0.28) (0.00–0.17)
Ampicillin QJ01CA 28 <0.01 <0.01 <0.01 <0.01 - -
(<0.01) (<0.01) (<0.01) (<0.01)
Ampicillin LA QJ01CA 11.25 <0.01 <0.01 <0.01 <0.01 - -
(<0.01) (0.00–0.08) (<0.01) (<0.01)
Amoxicillin QJ01CA 9 <0.01 <0.01 <0.01 <0.01 0.09 0.06
(<0.01) (<0.01) (0.00–0.01) (<0.01) (0.00–0.22) (0.00–0.14)
Amoxicillin LA QJ01CA 6.25 - - - - 0.32 0.28
(0.00–0.71) (0.00–0.72)
Amoxicillin+clavulanic acid QJ01CA 7 - - 0.05 0.04 - -
(0.00–0.15) (0.00–0.12)
Ceftiofur QJ01DA 1 0.30 0.15 0.01 0.01 2.32 1.27
(0.00–0.81) (0.00–0.34) (0.00–0.05) (0.00–0.05) (0.00–5.79) (0.00–3.07)
Cefquinome QJ01DA 1 0.06 0.04 - - 0.60 0.60
(0.00–0.19) (0.00–0.13) (0.00–3.14) (0.00–3.19)
Tylosin QJ01FA 7.5 - - - - 0.23 0.15
(0.00–1.30) (0.00–0.83)
Tilmicosin QJ01FA 10 - - 0.03 0.03 0.64 0.64
(0.00–0.14) (0.00–0.11) (0.00–2.14) (0.00–2.07)
Lincomycin QJ01FF 10 - - 0.02 0.06 - -
(0.00–0.05) (0.00–0.19)
Lincomycin+spectinomycin QJ01FF 5 0.01 <0.01 0.03 0.02 0.86 0.87
(0.00–0.02) (0.00–0.04) (0.00–0.27) (0.00–0.18) (0.00–2.41) (0.00–2.76)
Gentamicin QJ01GB 3.75 0.03 0.04 - - 0.02 0.03
(0.00–0.14) (0.00–0.17) (0.00–0.11) (0.00–0.16)
TMPd+sulphonamides QJ01EW 4.25 0.46 0.84 0.04 0.05 - -
(0.00–1.74) (0.00–3.46) (0.00–0.11) (0.00–0.18)
TMP+sulphonamides LA QJ01EW 1.2 - - - - 0.29 0.29
(0.00–1.63) (0.00–1.66)
Oxytetracycline QJ01AA 3 0.13 0.08 <0.01 <0.01 - -
(0.00–0.24) (0.00–0.22) (0.00–0.02) (0.00–0.16)
Enroﬂoxacin QJ01MA 2.5 0.25 0.21 <0.01 <0.01 0.78 0.52
(0.00–1.54) (0.00–1.45) (0.00–0.02) (0.00–0.06) (0.00–2.16) (0.00–2.08)
Danoﬂoxacin QJ01MA 1.25 0.01 <0.01 0.05 0.05 0.18 0.09
(0.00–0.03) (0.00–0.02) (0.00–0.19) (0.00–0.19) (0.00–0.50) (0.00–0.33)
Marboﬂoxacin QJ01MA 2 - - - - 0.09 0.05
(Continued)
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of animals at risk [9] in the veal herds, the number of animals was multiplied by the average
live body weight at the moment of treatment [4,8]. Because the majority of treatments in veal
calves were administered as group medication, these treatments were used to determine the
average live body weight at the moment of treatment. In the veal herds, a medicated starter
ration was defined as the treatment with antimicrobial drugs from the day of arrival on the
farm. The relative importance of each administered antimicrobial was expressed by the propor-
tional TIADD (UD) and the proportional TIUDD. These were calculated by dividing the TIADD or
the TIUDD of each antimicrobial by the total TIADD or the total TIUDD, respectively.
Table 3. (Continued)
Active substance ATCveta ADD Dairy herds Beef herds Veal herds
(mg/kg) TIADD TIUDD TIADD TIUDD TIADD TIUDD
(0.00–0.25) (0.00–0.28)
Florfenicol QJ01BA 10 0.03 <0.01 - - 0.22 0.30
(0.00–0.08) (0.00–0.02) (0.00–1.26) (0.00–1.68)
Colistin QJ01XB 50 - - - - 0.01 0.02
(0.00–0.04) (0.00–0.04)
Total (average) 3.01 2.36 3.78 2.15 6.74 5.21
aAnatomical Therapeutic Chemical classiﬁcation system for Veterinary medicinal products long acting
blong acting
cdihydrostreptomycin
dtrimethoprim. Recommended dosages, and thereby DDDs (deﬁned daily doses), according to more recent leaﬂets and registrations might differ (eg.
cephalosporines and ﬂuoroquinolones).
doi:10.1371/journal.pone.0146488.t003
Table 4. Average treatment incidences (min-max) based on the animal defined daily dose (ADD; TIADD) and the prescribed daily dose (UDD; TIUDD)
of the orally administered antimicrobial drugs in the veal herds (entire study period).
Active substance ATCveta ADD (mg/kg) Veal herds
TIDDD TIUDD
Amoxicillin QJ01CA 15 10.92 53.35
(0.00–43.67) (0.00–106.71)
Tylosin QJ01FA 16 12.34 271.64
(0.00–44.88) (0.00–393.80)
Trimethoprim+sulphonamide QJ01EW 30 17.09 17.01
(0.00–30.23) (0.00–28.34)
Oxytetracycline QJ01AA 30 62.40 62.89
(10.08–178.05) (12.85–143.63)
Doxycycline QJ01AA 10 21.06 52.86
(0.00–40.94) (0.00–76.70)
Colistin QJ01XB 5 13.75 27.56
(0.00–32.75) (0.00–40.94)
Flumequine QJ01MA 12 6.82 40.94
(0.00–20.47) (0.00–40.94)
Total 135.25 324.12
aAnatomical Therapeutic Chemical classiﬁcation system for Veterinary medicinal products
doi:10.1371/journal.pone.0146488.t004
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Bacteriology
For the isolation of E. coli, approximately 1 g faeces was diluted into 9 mL sterile PBS (phos-
phate buffered saline) and an aliquot was plated onto MacConkey agar (MAC; Oxoid, Basing-
stoke, UK) for overnight aerobic incubation at 37°C. Per sample, one colony of E. coli was
purified and identified as previously described (Catry et al., 2007a). Out of the nasal swabs, Pas-
teurella (P.)multocida andMannheimia (M.) haemolytica (sensu lato) were isolated on a selec-
tive medium (Columbia agar (Oxoid) to which 5% sheep blood and 16 μg/mL bacitracine were
added) and identified as previously described [6,7]. Strains were stored at -70°C prior to sus-
ceptibility testing.
Antimicrobial susceptibilities
After thawing at room temperature, bacteria were grown up overnight at 37°C on Columbia
sheep blood agar (Oxoid) under aerobic conditions and checked for purity. The antimicrobial
resistance profile was determined for each isolate by means of the Kirby-Bauer disk diffusion
method for following antimicrobial agents (abbreviation, content in μg): ampicillin (AMP, 33),
amoxicillin + clavulanic acid (AMC, 30+15), ceftiofur (CEF, 30), oxytetracycline (TET, 80), tri-
methoprim-sulphonamides (TMPS, 5.2 + 240), neomycin (NEO, 120), gentamicin (GEN, 40),
spectinomycin (SPT, 200), nalidixic acid (NAL, 130), flumequine (FLU, 30) and enrofloxacin
(ENR, 10). In addition, for Pasteurellaceae florfenicol (FLO, 30) was tested and for E. coli strep-
tomycin (STR, 100). CLSI guidelines (NCCLS-2002 M31-A2) were followed during the test
procedure for standardisation of the inoculum (0.5 McFarland), incubation conditions, and
internal quality control organism (Escherichia coli ATCC 25922). Media used were Mueller
Hinton II (Oxoid) for E. coli, and Mueller Hinton II with 5% sheep blood (Oxoid) for Pasteur-
ellaceae [6,7]. Reading of inhibition zones (in mm) was performed by the semi-automated
SIRscan 2000 device (i2a, Montpellier, France), and interpretation was done according to the
manufacturer of the disks (Guidelines for the use of Neosensitabs 18th Ed., 2005/2006, www.
rosco.dk). An isolate was considered ‘resistant’ if resistance or intermediate resistance was
observed for at least one antimicrobial agent tested.
Statistical analysis
For all bacterial species isolated, the resistance level was quantified by means of antimicrobial
resistance index (ARI) which is calculated as the number of antimicrobials against which resis-
tance is detected divided by the total number of antimicrobials tested [12]. Also for these analy-
ses intermediate results were considered resistant. The ARI can vary from 0.00 (0%), when the
strain is (fully) susceptible to every tested antimicrobial agent, to 1.00 (100%) when the strain
is (pan-) resistant to all tested antimicrobial agent classes. It enables to estimate selection pres-
sure exerted on one bacterium for different antimicrobial agents and can be used for different
bacterial species [6,13].
The relationship between the antimicrobial treatment incidences and the ARI was analysed
using a linear mixed effect model with herd included as random effect, and herd type and age
(in months) included as fixed effects. Hereby total treatment incidences (TIADD and TIUDD)
for the individual farms were considered, consisting of the sum of the different treatment inci-
dences for oral, parenteral, and topical use.
Analysis were performed with STATA version 10.0 (Stata Corporation, College Station, TX,
USA). The significance level was set P< or = 0.05.
The experimental protocol (sampling methodology) was approved by the local ethics com-
mittee (Ethical Committee of the Faculty of Veterinary Medicine).
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Results
Antimicrobial consumption data
Assessment of the quality of obtained antimicrobial consumption records resulted in a restric-
tion of the analysed period to 1 year in the participating herds, and 1 production cycle in the
veal calf farms. Detailed data on antimicrobial use by route of administration for the first year
of the study period in the 5 dairy and the 5 beef farms, and the average of the total production
cycle (6 months) in the 5 veal calf farms are presented in Tables 2 to 4. On 1 veal farm, the indi-
vidual parenteral treatments before 16 weeks of age were not recorded.
On the dairy herds, both topical (intramammary and intra-uterine) and parenteral formula-
tions were most commonly administered (Tables 2 & 3). The total TIUD for the intramammary
antimicrobial drugs was 2.8, which means that on a total of 1000 cows, 2.8 cows were treated
daily with a standard dose of an intramammary antimicrobial drug during the observation
period. Overall, the most frequently used intramammary antimicrobial drugs were beta-lacta-
mase resistant penicillins in combination with other antimicrobial drugs, beta-lactamase resis-
tant penicillins and cephalosporins. Their proportional TIUD were 29.3%, 27.6% and 27.4%,
respectively. The total TIUD for the intra-uterine antimicrobial drugs was 0.4 (Table 2). The
main indications to use intra-uterine cephalosporins and tetracyclines were retained fetal
membranes (retentio secundinarum) and endometritis.
For the parenterally administered antimicrobials, the total TIADD was 3.0. A comparison
with the TIUDD shows that in reality fewer animals were treated: 2.4 per 1000 on average in the
dairy herds (Table 3). For the most frequently injectable antimicrobials, the proportional
TIADD were: narrow-spectrum penicillins (31.2%), narrow-spectrum penicillins in combina-
tion with other antimicrobials (25.7%), trimethoprim-sulphonamide combinations (15.1%)
and cephalosporins (12.1%). Proportional TIADD were different from proportional TIUDD.
Mastitis was the main indication for the use of narrow-spectrum penicillins, and locomotory
problems were the main indication for the use of narrow-spectrum penicillins in combination
with other antimicrobial drugs.
The total TIADD on the beef herds was 5.4, whereas the total TIUDD was 4.9. Mainly paren-
teral antimicrobial drugs were used in the beef herds. Narrow-spectrum penicillins and nar-
row-spectrum penicillins in combination with other antimicrobial drugs (Table 3) were the
most often applied parenteral antimicrobial drugs. Their proportional TIADD were 70.4% and
23.3%, respectively. The main indication to use these antimicrobial drugs was surgical prophy-
laxis during caesarean section [14]. Fluoroquinolones were not frequently used (1.3%). The
total TIUD for the topical treatments was 0.9, compared to a slightly more frequent use in real-
ity (TIPDD = 1.2). Tetracyclines administered intrauterinely were the most frequently applied
topical antimicrobial drugs (88.7%). Surgical prophylaxis during caesarean section and
retained fetal membranes were the two main indications. Intramammary antimicrobial drugs
were not frequently used in the beef herds (Table 2). The oral treatments consisted of colistin
(polymyxin E) (92.2%) and trimethoprim-sulphonamide combinations (7.8%) for the preven-
tion and treatment of diarrhea (metaphylaxis) in calves.
In the veal herds, oral group treatments accounted for the largest amount of antimicrobial
drug use. Over the 6 month production cycle, the total TIDDD for the orally administered anti-
microbial drugs was 135.25, though in reality many more calves were treated with antimicrobi-
als since the TIUDD was 324.12 (Table 4). Tetracyclines (54.2%) and tylosin (24.2%) were used
most often. The main indication was prophylactic or metaphylactic treatment of respiratory
problems. On one farm (V1), tylosin was also used to prevent Clostridium perfringens entero-
toxaemia. The duration of the oral treatments generally varied between 5 and 13 days, but in
two occasions, tylosin was administered for 41 and 73 days, respectively. A significant amount
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of the oral antimicrobial drugs was given as a medicated starter ration (23.0%). Proportionally,
colistin (55.2%), oxytetracycline (29.5%) and trimethoprim-sulphonamide combinations
(10.1%) were most frequently used for this. Medicated starter rations were applied in all veal
herds and their duration varied between 6 and 13 days. For the injectable antimicrobials, the
TIADD was much lower, i.e. 6.7 (Table 3). The proportional TIADD for the most frequently used
injectable antimicrobial drugs were: cephalosporins (43.4%), fluoroquinolones (15.6%), macro-
lides (12.9%) and lincosamides (12.8%). In contrast with the dairy and beef farms where only
small variations were seen for treatment incidences over time, the treatment incidences on the
veal calf herds at the beginning and the end of the production cycle differed substantially.
Prevalence of bacteria and susceptibility profiles
The 10 dairy and 5 veal calf farms all completed the study (6 and 2 sampling moments, respec-
tively). Out of the 10 beef farms, only 9 remained in the study during the second and third sam-
pling moment, whereas only 7 herds completed the full study period (4 sampling moments)
(Table 5). Drop out of the study was due to loss of interest/ lack of time (n = 1) and termination
of livestock production (n = 2). In addition, the number of animals within several beef herds
dropped during the study period. Susceptibility profiles were determined for 4174 E. coli iso-
lates out of a total of 4552 rectal samples (91.7%) from the different sampling moments (range
84.2–98.7%) on the 10 dairy (2373/2549), 10 beef (1295/1468), and 5 veal calf herds (506/535).
During the two year study period, antimicrobial resistance among E. coli was in general rela-
tively stable in the dairy and beef herds (Table 5), with minimum-maximum values for the
average ARI per sample period for the dairy and beef herds of 0.00–0.096, and 0.00–0.196,
respectively. A slightly higher number of E. coli was resistant (or intermediate resistant) for at
least one antimicrobial agent in the beef herds (20.62%) compared to the dairy herds (12.05%).
The highest variability was seen for STR and TET in both herd types. The percentage of multi-
ple resistance (resistance for more than 3 agents) was 22.3% and 6.4% among the beef and
dairy isolates, respectively. The majority of multi-resistant strains (67.3%) were retrieved from
animals less than 6 months old. The resistance patterns most frequently encountered among
the isolates from the dairy herds were TET/STR (16.5%), TET (13.5%), and STR (11.5%).
Among the isolates from the beef herds, AMP/TET/STR (15.9%), TET/STR (11.4%), and
AMP/STR (9.8%) were the most prevalent.
In the veal calves herds, substantially higher values compared to the dairy and beef herds
were found and the minimum-maximum values for the average ARI per sample period were
0.284–0.759. Here, large differences were noticed between the first (T1) and second (T2) sam-
ple moment of the 6-month production cycle, especially for AMP, TMPS, NEO, GEN, SPT,
STR, NAL, FLU, and ENR (Table 5). Although the overall percentage of faecal E. coli isolates
resistant for at least one compound was highly comparable between T1 (97.83%) and T2
(98.82%), the number of multiple resistant isolates clearly decreased by the end of the produc-
tion cycle: whereas 68.9% of all strains at T1 were resistant for 7 or more antimicrobial agents,
only 12.4% of isolates at T2 were resistant for 5 or more antimicrobial agents. The most preva-
lent (24.8%) multi-resistance profile at T1 was AMP/TET/STR/NEO/GEN/TMPS/NAL/FLU/
ENR. At T2, the most prevalent (27.9%) resistant profile was AMP/TET/STR/TMPS. The
dynamical pattern of multiple resistances among E. coli in the veal calf herds is shown in Fig 2.
A total of 1217 nasal swabs were taken from 10 beef (682) and 5 veal calf (535) herds, result-
ing in 268 (39.3%) and 206 (38.5%) Pasteurellaceae strains from the beef and veal calf herds,
respectively, that underwent susceptibility testing. Two hundred and six P.multocida isolates
and 42M. haemolytica (sensu lato) isolates originated from the beef herds, whereas 163 P.mul-
tocida and 43M. haemolytica isolates originated from the veal calves. An overview of the
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resistance profiles, including the average ARI value per sample period, found for the Pasteurel-
laceae according to the production type of origin is given in Table 6. In the beef farms, the pre-
dominant resistance found was SPT (n = 44) which was found only on two farms. In one of the
latter herds, it was present during the 4 consecutive sampling periods in both P.multocida (4
periods, n = 41) andM. haemolytica (2 periods, n = 2). In the veal calf farms, 83.1% of all resis-
tant (or intermediate resistant) P.multocida isolates were resistant for at least 4 antimicrobial
Table 5. Overview of resistance percentages of E. coli during the consecutive sampling periods on the different production types.
Production
type
sample moment
(N herds)
N.
Isolates
ARIa AMPb AMC CEF TET TMP NEO GEN SPT STR NAL FLU ENR
Dairy I (10) 447 0.04 2.91 0.45 0.45 8.28 4.25 0.67 1.12 0.22 24.83 1.34 0.22 0
II (10) 396 0.01 2.02 0.25 0 3.79 0.25 1.52 0 0.25 4.55 0.76 0.25 0.25
III (10) 419 0.02 4.3 0.24 0 4.3 3.58 2.15 0.48 0 7.88 1.19 0.72 0.24
IV (10) 359 0.01 2.79 0.28 0.28 3.06 0.84 0.84 0 0 4.74 0.28 0.28 0.28
V (10) 382 0.02 5.24 1.05 0.26 3.66 3.56 0.52 1.05 0.79 8.64 0.79 0.26 0.26
VI (10) 370 0.02 3.24 0.54 0 5.14 1.89 1.62 1.08 0.54 6.76 1.35 0.54 0.27
Beef I (10) 436 0.03 9.17 1.15 0 6.88 4.13 2.52 0.92 0.69 13.3 2.52 0.46 0.46
II (9) 346 0.06 12.14 1.45 0.58 17.05 5.49 4.91 2.31 0.87 18.21 8.67 4.33 2.89
III (9) 298 0.05 9.4 1.34 0.34 12.08 6.71 5.03 1.01 0.34 13.76 5.03 4.36 2.35
IV (7) 215 0.09 17.21 1.4 0 15.81 6.05 7.45 2.33 1.4 24.19 8.37 5.12 4.19
Veal T1 (5) 276 0.62 93.12 4.71 0.36 94.93 92.75 83.33 45.29 22.46 89.49 79.00 73.13 64.23
T2 (5) 230 0.32 79.57 2.61 1.74 95.22 65.22 27.83 5.22 5.65 78.26 14.01 6.22 4.12
Overall (25) 4,174 0.09 17.08 1.24 0.26 19.03 13.75 9.67 4.52 2.37 22.02 8.74 6.70 5.58
a ARI: average antimicrobial resistance index (ARI) per sample moment.
b AMP, ampicillin; AMC, amoxicillin + clavulanic acid; CEF, ceftiofur; TET, oxytetracycline; TMP, trimethoprim-sulphonamides; NEO, neomycin; GEN,
gentamicin; SPT, spectinomycin; STR, streptomycin; NAL, nalidixic acid; FLU, ﬂumequine; ENR, enroﬂoxacin.
doi:10.1371/journal.pone.0146488.t005
Fig 2. Dynamical distribution of multi-resistance in veal calves. Proportion of strains (Y-axis, %) resistant
for indicated number of antibiotics (X-axis: 1AB; resistance to 1 agent tested, 2AB; resistance to 2 agents
tested, etc.) of faecal E. coli (N = 506) retrieved during the production cycles at T1 (blue bars; 4 weeks +- 5
days after arrival, N = 276) and T2 (red bars; 24 weeks +- 5 days after arrival, N = 230) from 5 veal calves
farms.
doi:10.1371/journal.pone.0146488.g002
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agents at T1. At T2, multiple resistances had decreased with 58.3% of all strains showing resis-
tance to maximum 2 compounds tested. The most predominant resistance profile of P.multo-
cida at T1 was GEN/TMS/FLU/NAL (58%). At T2, the latter pattern had decreased to the
second most resistance profile (19%) after TET (58%). Among the resistantM. haemolytica iso-
lates from the veal calves, 80% was resistant for 4 or more antimicrobial agents at T1. Similarly
to the situation for P.multocida, multiple resistance decreased at T2, with 74% of the resistant
M. haemolytica strains showing resistance to 1 or 2 compounds. At T1, resistance towards
AMP/TET/GEN/TMPS/NAL/FLU/ENR was most common (30%), whereas at T2 the most fre-
quent combinations of resistance were AMP/TET (35%) and AMP (32%).
Relationship between antimicrobial use and resistance
Association between the treatment incidences of antimicrobial agents (TIADD and TIUDD) and
antimicrobial resistance (ARI) was tested for a total of 1639 E. coli isolates from 5 dairy (1year;
3 sampling periods, N = 635), 5 beef (1 year; 2 sampling periods, N = 497), and 5 veal calf herds
(6 months; T1; N = 276, T2, N = 231). Over the three production types, a significant relation-
ship was found by multivariate analysis between the ARI for E. coli with the TIADD (P<0.001)
and TIUDD (P<0.001), with herd type showing a significant effect (P<0.001) but age did not
(P>0.35).
The association between treatment incidences and ARI was investigated for 309 Pasteurella-
ceae originating from 5 beef (2 sampling periods, N = 102) and 5 veal calf farms (T1; N = 93,
T2; N = 114). At the beef and veal calf herds, the ARI of the Pasteurellaceae showed a signifi-
cant effect with the TIADD (P = 0.012) and TIUDD (P = 0.002). In these analyses, also the herd
type was demonstrated to exert significant effect (P = 0.012).
Thus, analyses of both faecal E. coli and respiratory Pasteurellaceae demonstrated a signifi-
cant difference in occurrence of antimicrobial resistance directly related to the production
type. In addition to this effect, the consumption of antimicrobials also largely influenced the
occurrence of antimicrobial resistance in both the digestive (E. coli) and the respiratory tract
(Pasteurellaceae).
Discussion
In the present study, the antimicrobial use was monitored in bovine herds using a multi-centre
approach and an intensive sample strategy of the digestive and respiratory tract. The approach
Table 6. Overview of resistance percentages of Pasteurellaceae during the consecutive sampling periods on the different production types.
Production
type
sampling
moment (N
herds)
N.
Isolates
ARIndexa AMPb AMC CEF TET TMP NEO GEN SPT FLO NAL FLU ENR
Beef I (10) 94 0.03 0.00 0.00 0.00 0.00 17.78 1.11 1.11 15.56 0.00 1.11 1.11 0.00
II (9) 78 0.01 1.49 0.00 0.00 0.00 2.99 0.00 0.00 10.45 0.00 0.00 0.00 0.00
III (9) 42 0.03 0.00 0.00 0.00 0.00 2.63 0.00 0.00 28.95 0.00 0.00 0.00 0.00
IV (7) 54 0.02 0.00 0.00 0.00 0.00 0.00 2.04 2.04 24.49 0.00 0.00 0.00 0.00
Veal T1 (5) 93 0.27 8.60 0.00 0.00 38.71 50.54 45.16 43.01 4.30 0.00 48.39 44.09 36.56
T2 (5) 113 0.15 29.82 0.00 0.00 42.98 29.82 18.42 14.91 1.75 0.00 19.30 16.67 10.53
Overall (15) 474 0.11 9.53 0.00 0.00 18.85 22.17 14.41 13.08 11.09 0.00 15.08 13.53 10.20
a ARI: average antimicrobial resistance index (ARI) per sample moment.
b AMP, ampicillin; AMC, amoxicillin + clavulanic acid; CEF, ceftiofur; TET, oxytetracycline; TMP, trimethoprim-sulphonamides; NEO, neomycin; GEN,
gentamicin; SPT, spectinomycin; FLO, ﬂorfenicol; NAL, nalidixic acid; FLU, ﬂumequine; ENR, enroﬂoxacin.
doi:10.1371/journal.pone.0146488.t006
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was original since it allowed prospectively investigating associations between antimicrobial
drug use and antimicrobial resistance simultaneously in two ecosystems. Due to the intensive
sampling and registration protocol that required well motivated farmers it was not possible to
select the herds at random. Another limitation of the study design was information bias in the
herds due to incomplete or inaccurate consumption records. Also, the here applied treatment
incidences only give indirect information on the duration (length in days) of therapy [4], while
this contributing factor is not taken into account during the analysis. For the susceptibility test-
ing the disk contents (μg active antimicrobial agent in tablets) deviated from CLSI standards
and the diffusion test for Pasteurellaceae is known to have clear limitations for certain antimi-
crobial compounds [7]. The here applied primary variable of interest was the antimicrobial
resistance index (ARI) [12]. It is a straightforward way to describe multidrug resistance across
different bacterial species, and enables to model a historical selection pressure within a certain
ecological niche [6]. The ARI is function of related resistance mechanisms over different com-
pounds tested (e.g. the quinolones; cross-resistance) and can be strongly influenced by linked
resistance genes (e.g. plasmids; co-resistance). To exclude a major influence of related resis-
tance determinants inherent to our selection of antimicrobial agents, the analysis between TI
and antimicrobial resistance among faecal E. coli was repeated ([13]–S1 File). Therefore we
redefined the ARI upon only 7 antimicrobial compounds (AMP, TET, ENR, GEN, SPT, NEO,
TMP) instead of 12, and the analysis confirmed a similar significant association with the TIPDD
(P<0.001) and with the TIDDD (P<0.001), suggesting the bias due to the choice of antimicro-
bial agents was not substantial.
In relation to the reliability of our antimicrobial consumption records, no large discrepan-
cies were seen in our antimicrobial consumption data with regard to main indications and anti-
microbial classes compared to previous reports on 110 randomly selected dairy herds [15], on
105 selected beef herds [16] and on 6 [17] and 15 [8] veal calf farms. Our results also demon-
strated substantially large differences in antimicrobial consumption patterns between the herd
types. This was illustrated by means of both the ADD and the UDDmethodology. From the
TIUDD calculations, it was shown that the largest deviations from the recommended regimens
according to the leaflets were mainly restricted to the veal calves. About 2.5 times more veal
calves were treated with antimicrobial agents than the number of calves for which that amount
-present on the farm- was intended (Table 4), resulting in 88.0% of oral administrations that
were underdosed. A similarly high degree of underdosing was also found in 50 randomly
selected Belgian swine herds and was also seen for oral group treatments [4]. On the other
hand, in the porcine study injectable antimicrobial agents were mostly overdosed, which is in
line with the here presented bovine data. As these factors are of relevance for the development
of specific guidelines for a judicious use of antimicrobial agents [18], the underlying reasons
for choosing between oral and injectable antimicrobial regimens have been discussed before in
detail [4].
For long Escherichia coli has been used in order to measure antimicrobial resistance in a
variety of ecological niches, including human and animal settings. In adult dairy cattle, resis-
tance among E. coli was sparse and in agreement with an Australian study by Jordan and col-
leagues [19]. The age related decline in overall resistance of enteric E. coli, irrespective of
antimicrobial use [2, 20–21], was also reflected here on the extensively reared herds. Detailed
studies have suggested that this might be the consequence of an effect of milk diet (in particular
a vitamin D component) to select for multi-resistant E. coli in calves [22]. The here found
remarkable dynamical shift in resistance profiles over the production cycle in the veal calves
might reflect this effect of the milk diet, combined with what has been postulated based on sim-
ilar observations in swine [21], namely that following oral administration of antimicrobial
agents a relatively large number of resistant strains occurs in the faeces rather than the
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dominance of a limited number of resistant clones. Before arrival in the veal herds, calves
might have been fed waste milk from intramammary treated dairy cows at the herd of origin.
This practice might also have exerted a selection pressure. At the time of the investigations,
veal (white) calves were usually raised solely on a milk diet throughout the entire production
cycle, whereas other calves are weaned at the first half of the same age period.
The sampling strategy for faecal E. coli was very intense compared to other surveillance or
monitoring programmes, in which resistance percentages of cattle isolates were always found
to be in favour compared to swine and poultry [23–25]. Our results are in line with a distinc-
tion in resistance abundance at slaughter between veal calves [26] and less intensively reared
beef or dairy cattle [3,23], which is relevant for public health surveillance. Compared to our
observations, Sawant et al. found a very high frequency of resistant E. coli’s among adult dairy
cattle [27]. This is likely the consequence of the use of selective media containing antimicrobi-
als procedure known to substantially increase the sensitivity of rating antimicrobial resistance
among Enterobacteriaceae.
Of the many studies dealing with resistance of E. coli in cattle, the number of studies includ-
ing detailed antimicrobial consumption records is sparse. In agreement with our study, Berge
et al. experimentally found that in-feed antimicrobials were associated with higher levels of
multiple antimicrobial resistance whereas individual antimicrobial therapy was associated with
increased but transient resistance [1]. Similarly, Di Labio et al. [28] also found a protective
effect of antimicrobial injection upon arrival versus in milk medication (oral) for antimicrobial
resistance in Swiss veal calves. Recent research has also highlighted the difference of route of
administration with regard to number of both resistant bacteria and genes in the intestinal
tract [29–30]. The marked differences in ARI between intensively reared veal calves and the
other production type also results likely from the different predominant route of administra-
tion across these settings. The selection pressure exerted by a certain therapy on a certain
microbiome, indeed, is influenced by pharmacokinetics like absorption rate, protein binding,
metabolisation, elimination half-life, tissue distribution, and enterohepatic cycling.
In human medicine, observations in E. coli have revealed that treatment incidences
(TIDDD), for one particular compound or related agents, are not always associated with resis-
tance for that compound, while in general total antimicrobial consumption (TIDDD) can corre-
late well with the occurrence of antimicrobial resistance [31]. In agreement with the latter
study, we found the ARI derived from E. coli to be significantly associated with the two con-
sumption parameters TIADD and TIUDD. A relationship between the consumption of a certain
antimicrobial compound and the occurrence of resistance in the digestive tract (or co-selected
traits by linked resistance genes), has been documented for particular molecules in different
animal species for E. coli and for other commensal bacteria like enterococci [1,32].
A significant association was found between antimicrobial consumption and the occurrence
of resistance in the respiratory tract, through screening of Pasteurellaceae, among the most
important bovine—and in a larger context veterinary—respiratory pathogens. Malhotra-
Kumar et al. have shown in a randomised controlled clinical trial that a selection pressure
exerted by oral antimicrobial therapy also is reflected in the resistance situation of commensal
oral streptococci, and the authors refer to these bacteria as a source of resistance genes for
respiratory pathogens [33]. Our observational study design comparing exposed versus non
exposed animals was able to demonstrate that opportunistic respiratory pathogenic bacteria
themselves can act as a reservoir of resistance. In view of the similarities of respiratory disease
over the different animal species, with Pasteurellaceae (e.g. Haemophilus influenzae) or other
secondary invaders being involved frequently, it seems plausible to believe that identical pro-
cesses are taking place when a certain critical antimicrobial consumption level is attained.
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A high population density combined with cross-infection and co-selection are suspected to
increase the risk for the spread and persistence of antimicrobial resistance, as seen in human
medicine for intensive care units [34]. In livestock, similar conditions have been found in
intensive production systems like industrialised poultry [32] and swine [5], and our results
indicate this is also applicable to densely housed veal calves. Antimicrobial resistance selection
plus specific persistence over consecutive production cycles [32] can explain the intense accu-
mulation of resistance in these production systems. In every instance, the high infection pres-
sure among young (immunity-impaired) transported animals from a diverse geographical
origin [17] implicates that in the near future and in these settings antimicrobial therapy
remains necessary to minimise economic losses by bacterial infections.
In conclusion, large deviations from registered dosing regimens were found in the veal
calves for oral antimicrobial group treatments. A significant association between antimicrobial
use and resistance was confirmed for enteric E. coli and simultaneously demonstrated for respi-
ratory pathogenic Pasteurellaceae. The results provide strong evidence that conditions in the
veal calf industry are able to generate reservoirs of resistance among both commensal and ani-
mal pathogens. Therefore, in our opinion and in accordance with the Dutch surveillance sys-
tem [25], intensively reared veal calves deserve special attention in antimicrobial resistance
monitoring and intervention programmes.
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